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Forecasting New Product Trial with Analogous Series 
 
Abstract 
 
     This study develops a simple method for forecasting consumer trial for national product 
launches. The number of consumers who try a brand in its first year on the market is accurately 
predicted from the number trying the brand in the first thirteen weeks following launch. No 
information about the specific category or marketing activities is required– just a simple 
multiplier computed from analogous series in other markets. These analogues provide an 
empirical generalization that can be easily applied by practicing managers to track and forecast 
the success of new brand launches. When subject to an out-of-sample test involving 34 fresh data 
sets, the analogues demonstrated 43 percent reduction in Mean Absolute Percentage Error 
compared to the most accurate marketing science model.  
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1. Introduction   
Accurate forecasts of new product performance have many uses: they help to decide whether to 
launch the new product; they guide production plans and optimal stock levels; they encourage 
sales and retailer support; and they provide benchmarks for sales targets over the first year. 
Although there are many complex marketing science models available for making new product 
forecasts, these complex models are rarely (if ever) used by managers, and when forecasting is 
undertaken its performance remains notoriously poor. For example, Khan’s (2002) survey of 
marketing managers asked them to report the level of accuracy achieved for their new product 
forecasts; he found that self-reported forecast accuracy averaged just 58 percent, dropping to 47 
percent for new category entrants and 40 percent for products that were new to the world. 
The present work addresses one part of this problem, by developing forecasts and 
benchmarks for growth in consumer trial over the first year of sales. Consumer trial is the 
proportion of the target market who purchase once or more in a given period after product 
launch. Consumer trial is a simple measure and one of the most commonly used metrics for 
evaluating new product launch as it is easy to gather via syndicated panel data or ad-hoc tracking 
surveys (e.g. using the question “have you ever bought/tried this product?”). Logically, consumer 
trial is a hurdle which must be cleared before repeat purchase and long-term sales can be 
established. 
Strictly speaking, the first purchase is not the same as the sociological concept of a trial. 
Trialability is an important characteristic of innovations in the diffusion literature, and may be 
promoted through, for example, a test drive for a car, product sampling or a first purchase of a 
frequently consumed product. For durables such as cars, first purchases are adoption rather than 
trial, and even if followed by replacement or disenchantment discontinuance the purchase was 
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nonetheless adoption and not just trial; see Rogers (1995) for further discussion of these 
concepts. For frequently purchased products, there is some argument about whether the first 
purchase represents trial, immediate adoption, or simply a rate of purchase that may be revised 
up or down depending upon satisfaction with the product experience; see Fader et al. (2003) and 
East, Wright, and Vanhuele (2013) for a discussion of this issue and the associated literature. In a 
similar vein, Meade and Islam (2001) distinguish the adoption process (e.g. for durables) from a 
consumption process (e.g., for packaged goods) in which adoption choices are revocable. Despite 
these complications, common usage applies the term trial to the cumulative penetration metrics 
obtained for new products from consumer surveys for consumption processes. The present work 
follows common usage, with consumer trial referring to those who have bought a newly 
launched frequently purchased product at least once. 
Consumer trial has long been forecast using marketing science models, although there are 
few systematic evaluations of the performance of these models. Meade and Islam (2001) assess 
adoption models in which choices are not easily revocable. Hardie, Fader and Wisniewski (1998) 
– hereafter HFW – evaluate consumption models for frequently purchased products in 
BehaviorScan controlled test markets (see also Fader and Hardie 2001 and Fader, Hardie and 
Zeithammer 2003).  
More recent work extends these modeling approaches by introducing additional complexity. 
Du and Kamakura (2011) apply an individual-level trial hazard model to evaluate the role of 
contagion in the diffusion of new product trial. Liutec, Du, and Blair (2012) develop Du and 
Kamakura’s model (2011) using BehaviorScan data; they describe their approach as follows: 
The actual forecasting procedure has several steps. First, estimates for the historical 
set of products are obtained. Second, these estimates are used as priors for estimation of 
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the “forecasting model”, which is calibrated on data for both the focal product (first 
weeks available post launch, and incorporating more observations as they become 
available) and the historical adoption data. Third, posterior estimates for all (focal) 
product-level and individual level parameters are computed (e.g., Train 2003). Finally, 
the posterior estimates obtained above are used to simulate out-of-sample purchases for 
the focal product. More specifically, many out-of-sample “purchase paths” are simulated 
for each consumer, then averaged across the number of simulations and summed across 
consumers.  (Liutec, Du. and Blair, (2012, p. 17)  
The complexity of Liutec et al’s approach may prevent widespread utilization by marketing 
managers. Further, much of the evaluation of the consumer trial models takes place in 
BehaviorScan controlled test markets, and it is unclear how well these models will generalize to 
the different context of national product launches. 
While the BehaviorScan markets used by HFW and Liutec at al. (2012) possess many 
attractive features, such as high levels of marketing control, immediate distribution, and 
provision of complete information on purchases, they are restricted to small test cities with 
relatively homogenous populations. BehaviorScan market tests are expensive, are only available 
in a few countries, and are restricted to grocery products. They are not necessarily representative 
of broader domestic or international markets. In contrast, most brand managers rely on panel 
tracking or survey data to assess the performance of new products. The trial curves observed in 
test markets may not generalize to national launches due to the uncontrolled environment and 
varied populations involved. These varied populations may adopt simultaneously, as with test 
markets, or serially, and this may vary between countries (e.g. see Meade and Islam 2001). 
5 
 
 
Therefore, the first objective of the present work is to extend the analysis of forecasting 
performance of the marketing science models of consumer trial from test markets to national 
launches. This provides baseline results against which a simplified forecasting technique can be 
compared. Simplified forecasting techniques are desirable as even the best marketing science 
model may be limited in its practical application. Khan (2002) finds the more popular statistical 
forecasting techniques for new products are trend line and moving average analysis. Techniques 
such as diffusion, ARIMA or regression are rarely utilized, and one reason for this could be the 
impact of a ‘bias’ in forecasting Gigerenzer and Brighton, (2009); Brighton and Gigerenzer (this 
issue). Overall, Khan (2002) finds a preference for qualitative techniques.  
Analogous series is a simpler quantitative technique that can be applied to forecast consumer 
trial. Duncan, Gorr and Szczpula (2001) argue that pooling of analogous series improves 
forecasting accuracy when time series are highly volatile or when they have outlier data points. 
As consumer trial frequently shows early fluctuations in the data (volatility) analogous series are 
an appropriate method of analysis. If successful, they may provide an empirical generalization 
that is easily applied by managers, helping to resolve the forecasting performance issues 
identified by Khan (2002). That is, analogous series would provide managers with a simple and 
successful quantitative tool for forecasting consumer trial of new products. 
Therefore, the second objective is to apply the simpler technique of analogous series to 
forecasting consumer trial, and to compare the results with those of the marketing science 
models. Analogous series comprise  
data that are expected to be related and are conceptually similar. Such series are  
 expected to be affected by similar factors (Armstrong, 2001, p. 764).   
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The final objective is to evaluate the results for analogous series using out-of-sample tests 
with fresh data sets. This gives more confidence in the generalizability of the findings. 
The remainder of the paper is structured as follows: Section 2 introduces the data used in the 
initial studies. Section 3 extends the baseline marketing science models from 19 controlled test 
market product launches to the context of 12 national product launches. Section 4 develops and 
applies the analogous series to these 31 examples of controlled test markets and national product 
launches. Section 5 applies the analogues for national product launches to a further 34 out-of-
sample test data sets. The paper concludes with a discussion and summary. 
 
2. Data 
The data for the baseline comparison of marketing science models are cumulative trial panel data 
sets for 12 new product launches from three countries. Commercial confidentiality prevents full 
description, but a summary appears in Table 1. The data are a mix of really new products, line 
extensions and simple variants. The New Zealand data are provided courtesy of AC Nielsen 
Homescan. The USA data are provided by a marketing science consultant. The data on UK drug 
prescribing come from Jigsaw, a commercial panel of UK General Practitioners operated by 
Synovate. The four drugs analyzed are Didronel used to treat osteoporosis, and three new drugs 
used to treat hypertension: Cozaar was the first to market followed by Diovan (a me-too) two 
years later and Amias (another me-too) launched a year after Diovan.  
 
Table 1 here. 
 
The range of product categories studied is deliberately diverse to provide a strong test of the 
analogous series approach. As well as geographical differences there are varying degrees of 
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innovativeness, and even general practitioners’ prescriptions of new drugs. Although 
qualitatively very different, patterns of prescribing behavior for existing drugs are known to be 
similar to patterns of purchase behavior for packaged goods (Stern and Ehrenberg, 1995) and so 
are suitable for this analysis. 
The results for these data are compared with the results for 19 BehaviorScan cumulative trial 
data sets provided online at brucehardie.com. Sample sizes for the BehaviorScan data sets range 
from 566 to 2946 and average 1146. No details are provided about the individual brands. 
The performance of the analogous series prompts an examination of further data as a check 
on the initial results. This uses 34 fresh test data sets, consisting of cumulative trial panel data for 
GP’s prescriptions of new drugs. Sample sizes range from 272 to 460 and average 373. The 
sample sizes are slightly smaller but of the same magnitude as those used by HFW. These data 
include new products from a variety of categories ranging from antidepressants, to drugs for 
lowering cholesterol, treatments for erectile dysfunction and rheumatoid arthritis, and widely 
differing degrees of innovativeness and success. 
 
3. Method and Results – Baseline Models  
The work of HFW guided the selection of the baseline marketing science models. Many 
marketing science models of consumer trial include the exponential, exponential gamma, 
Weibull-gamma, lognormal-lognormal, double exponential and Bass models. In some cases, 
these models are further complicated by the inclusion of a never-triers parameter or a stretch 
parameter. HFW compare the forecasting performance of eight such models using 52 weeks of 
data for each of 19 BehaviorScan data sets. They used both 13-week and 26-week calibration 
periods and examine forecasting performance for the remaining weeks using Forecast MAPE 
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(mean absolute percentage error), to show the evolving performance of each model as well as the 
difference between forecast and actual trial at fifty-two weeks (52 Week APE, or absolute 
percentage error). They find the four simpler exponential trial growth models provide more 
accurate forecasts than the four more complex models (Weibull with never triers, Lognormal-
Lognormal, Double Exponential and Bass). In subsequent work they abandon these complex 
models and also a fifth model, the gamma never-triers with stretch (Fader and Hardie 2001) due 
to the logical inconsistency of the formulation which can lead to trial proportions exceeding 
unity (Hardie 2006 Personal Communication). 
The present work therefore restricts use of baseline marketing science models to the three 
that survived HFW’s winnowing. These are, in order of decreasing simplicity; an exponential 
model with a segment of never-triers, the exponential gamma model (which is the purchase-
timing analogue of familiar Negative Binomial Distribution model (Ehrenberg, 1959)), and the 
exponential-gamma model with a segment of never-triers.  
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3.1 Model Specification 
HFW note their exponential with never-triers model arises from the well-known approach of 
Fourt and Woodlock (1960). They propose a continuous-time revision of this model to 
incorporate a segment of never-triers, as follows: 
 
P (t) = p (1 – e –t)       (1) 
 
 where P(t) = cumulative trial of the new product at time t, 
  p = proportion that will ever try the new product, 
 = probability of trial, given that trial has not yet occurred, 
for those that will ever try the new product, 
t = time period since launch. 
 
Consumer heterogeneity is added to this model by allowing the purchase rate to vary across 
the population. This is achieved using a gamma distribution with scale parameter  and shape 
parameter r, leading to the following exponential-gamma model: 
 
  P (t) = 1 – ( / ( + t)) r       (2) 
 
Adding back the allowance for never-triers yields the third model, exponential-gamma with 
never triers: 
 
  P (t) = p [1 – ( / ( + t)) r]       (3) 
10 
 
 
 
3.2 Estimation 
Estimation is through non-linear least squares (NLLS) using cumulative trial. This involves 
minimizing the sum of the squared errors between estimated and actual cumulative trial using the 
iterative procedures available in standard commercial software packages. HFW find this 
approach produces better results than NLLS using non-cumulative trial, and similar results to 
maximum likelihood estimation. Although maximum likelihood estimation is theoretically 
superior, the empirical results are only marginally better (Fader and Hardie 2001, p625). NLLS 
can be computed using the Solver function in Excel, making both replication and practical 
application of this approach easier. Following HFW, model estimation is based on 13-week and 
26-week calibration periods. 
The USA data sets have some missing data. These data are aggregated into four-weekly 
intervals, so values for weeks 13 and 26 are not available. They are interpolated using a simple 
linear model. These imputations are used for model fitting only, and not to assess forecasting 
performance. Also, one New Zealand product launch has only 47 weeks of data with a maximum 
183 cumulative trialists. The interpolated value for week 52 is imputed as 189 trialists; this value 
yields identical 52-week percentage errors to the other 11 data sets, and so does not bias the 
estimate of 52-week forecast performance. 
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3.3 Results 
For the 13-week calibration period, Table 2 shows forecast period mean absolute percentage 
error (Forecast MAPE, also called Tracking MAPE) and 52-week forecast absolute percentage 
error (52w_APE) for the three models. The Forecast MAPE shows how closely the estimated 
cumulative trial curves track empirical cumulative trial, while the 52-week APE assesses the 
accuracy of the forecast of year-end cumulative trial. Each number represents the average across 
all twelve data sets, based on the 13-week calibration period. The equivalent results obtained by 
HFW from their 19 BehaviorScan test market data sets are included for comparison. Smaller 
numbers indicate lower forecast error. 
 
Table 2 here. 
 
Comparing the three rows of alternative models, the differences in relative performance 
within each set of data are small. In each case, any one model performs about as well as any 
other, although the simpler Exp.-Gamma model performs best overall. However, comparing the 
column means between the two sets of data, the Forecast MAPE for national launches is almost 
double that found using the BehaviorScan data (28 percent versus 16 percent). This is likely due 
to the greater variety among the national launches, including more differences between 
customers, more random disturbances and greater marketing variations when moving from 
BehaviorScan test markets to panel tracking data. Despite this, the 52-week APE values are 
reasonably close across both sets of data, albeit slightly smaller for the test markets.  
Table 3 provides an identical analysis for the 26-week calibration period. As expected the 
longer calibration period results in improved forecasting performance. The results for national 
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launches are now comparable with those found by HFW, and in fact are slightly better. This 
confirms that the original pattern of results found by HFW can be extended to national product 
launches, with the proviso that a 26-week calibration period is necessary to achieve comparable 
accuracy to BehaviorScan test markets. 
 
Table 3 here. 
 
These results are consistent with several of the forecasting principles reported by Fader and 
Hardie (2001): that is simpler models perform well; that including consumer heterogeneity 
(variation in purchase rates) improves forecasts; and that a never-triers parameter does not 
improve Forecast MAPE.  
Despite the different patterns of trial growth, the marketing science models used in test 
markets can be extended to national panel data and this provides a baseline against which the 
performance of analogous series can be compared for both national product launches and 
BehaviorScan test markets. 
 
4. Method and Results – Analogous Series  
Implementing analogous series first requires that all cumulative trial curves are made directly 
comparable. This involves converting trial figures into proportions then, for each data set, 
calculating the ratio of Week <x> cumulative trial to 52-week cumulative trial, which normalize 
each period’s trial to year-end values. For forecasting, the average of these values for any 
particular period t, is used to estimate the proportion of year-end cumulative trial achieved by 
period t.  
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Formally, 
 
 Pj (t) = (1 / n)  ∑ j = 1 to n  ( pjt / pj52 )        (4) 
 
 Where  Pj (t)    =   average proportion of 52-week cumulative trial achieved by 
time t, for the group of data sets j, where j varies from 1 to n 
pjt  = cumulative trial for new product j at time t 
pj52 = cumulative trial for new product j at Week 52 
  
Equation (4) uses all the data available to identify the analogous empirical pattern. While 
this is the best estimate of the analogous series for future applications, this is not appropriate for 
assessment of forecasting performance; by including all the data sets, Equation (4) includes the 
values to be forecast. Assessing the accuracy of analogous series requires a modification to omit 
the data set under consideration (j=i), as follows. 
 
 Pi (t) = (1 / (n-1))   ∑ j = 1 to n, j  i (pjt / pj52)       (5) 
 
This gives, for each data set, the analogous pattern present in all the other data sets. This is 
used to forecast the focal data set as shown Equation (6). This specification allows measures of 
forecast error to be calculated in exactly the same way as for the exponential trial growth models 
in Equations (1) to (3). 
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 Pi52  = pit  / Pj (t)        (6) 
 
In BehaviorScan test markets cumulative trial grows more quickly than in national product 
launches, probably due to their homogenous populations, immediate distribution and tightly 
managed marketing programs. This is part of the purpose of BehaviorScan test markets; as by 
achieving trial more quickly they allow a faster assessment of the test brand. Thus separate sets 
of analogues are calculated for national product launches and BehaviorScan test markets.  
Table 4 shows the results. The second and third columns report the proportions of year-end 
trial, which are the average ratios across all data sets using equation (4); in other words, the 
analogous series. The next two columns show the 52w_APE values for the estimates derived 
from equation (5) and (6).  
 
Table 4 here 
 
The forecasting errors (52w_APE) are highest soon after launch when the least data is 
available. Forecast errors from national launches are higher than those from BehaviorScan test 
markets initially, but become lower once 13 weeks of data are available. Consistent with another 
principle that Fader and Hardie (2001) propose, lengthening the calibration period eventually 
ceases to have much impact on accuracy – in this case, at around 26 weeks. 
So far, this pattern of results is qualitatively similar to that found for the marketing science 
models. In order to assess how analogous series perform, the 52w_APE values in Table 4 are 
compared with the 52w_APE values in Tables 2 and 3. 
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For national product launches with a 13-week calibration period, the analogous series value of 13 
is much lower than the values of 27, 29 and 30 for the marketing science models. For a 26-week 
calibration period, the analogous series value of 6 is much lower than the values of 9, 9, and 10 
for the marketing science models. (US national launches do not include data for the 26-week 
period; however, they do include data for the 24-week period, and the analogous series for 24-
weeks has a 51w_APE of 10.) 
For BehaviorScan test markets with a 13-week calibration period, the analogous series value of 
23 is similar to or lower than the values of 23, 24 and 24 for the marketing science models. For 
26-week calibration period the analogous value of 11, is lower than the values of 12, 12 and 18 
for the marketing science models  
 
Thus, the analogous series provide comparable or better estimates than the marketing science 
models. Analogous series dominate the three more complicated models. In the case of the 
simplest exponential-gamma model, the analogous series has lower forecast error for three of the 
comparisons, and equivalent forecast error for the fourth. 
 
5. Method and Results: Additional Data sets 
The initial results are surprising and so should be checked using challenging tests against 
competing approaches. This is accomplished with the use of 34 additional pharmaceutical data 
sets, obtained after the initial analysis was completed, to determine how well the analogous 
series for the original 12 national product launches predicts for genuinely new data. 
 Figure 1 presents the average of the normalized cumulative trial proportions for all three 
data sets – the 19 HFW BehaviorScan test market data sets, the 12 national product launch data 
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sets, and the 34 extra pharmaceutical test data sets.  In other words, Figure 1 presents the two 
analogous series from Table 4, and a new analogous series calculated from the 34 additional 
pharmaceutical test data sets. 
 
Figure 1 here. 
 
The pattern of growth in normalized cumulative trial proportions for test markets differs 
from the other series; this is as expected, due to the controlled conditions present in the test 
market.  In contrast, the analogous series for national launches and extra pharmaceutical data sets 
are similar. This similarity implies the analogous series approach will fit the extra 
pharmaceutical data sets on average; however, this does necessitate accurate forecasting 
performance, as individual data sets vary considerably around the series average, as appearing in 
Figure 2. 
 
Figure 2 here 
 
The competing approaches against which the analogous series is assessed are a naïve 
straight-line growth in cumulative trial, and the exponential-gamma marketing science model. As 
before, forecasts are made at 13 and 26 weeks, and evaluated using Forecast MAPE and 
52w_APE, together with a new measure of 52w_MPE, defined as the mean percentage error, or 
bias, of the 52 week forecast. A positive value of 52w_MPE indicates the actual trial is higher 
than the forecast trial.  
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Table 5 shows the results, including a summary of the performance of the exponential 
gamma model previously reported in Tables 2 and 3. These results are not directly comparable 
with the new analysis, but do provide a reminder of the magnitude of typical forecast errors for 
the best performing marketing science model. 
 
Table 5 here. 
 
The naïve comparator of a straight line provides a surprising challenge, with forecast 
(tracking) MAPE within the range of values typically found for the exponential-gamma model. 
However, the exponential-gamma model does still outperform the naïve comparator and 
substantially so on 52w_APE and 52w_MPE.  
 More generally, the fit of the exponential-gamma model is almost as accurate as for the 
other 31 data sets examined. While forecast errors are a few points higher, this is not surprising 
given the smaller sample sizes in the 34 test data sets (averaging 373 compared to 1146 for 
BehaviorScan and 2039 for the national product launches).  
 Nonetheless, the analogous series out-performs both other methods. For the 13-week 
calibration period the analogous series dominate the exponential-gamma method over all three 
measures of forecast error with a 43 percent reduction in Forecast MAPE, an 8 percent reduction 
in 52w_APE, and a lower level of bias as shown by 52w_MPE. For the 26-week calibration 
period, the analogous series out-perform the exponential gamma method on two measures of 
forecast error with a 38 percent reduction in Forecast MAPE and a 14 percent reduction in 
52w_APE, and closely follow on the third measure of 52w_MPE. Further, the value of 2 percent 
for 52w_MPE indicates minimal bias arising from the analogous series approach in the 26-week 
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calibration period. Again the simplest model – in this case the analogous series - works best, 
consistent with forecasting principles proposed by Duncan, Gorr and Szczpula (2001), Fader and 
Hardie (2001), and Meade and Islam (2001).  
 Should the analogous series in Table 4 include values from the 34 test data sets? The 
appropriateness of doing so is unclear, and the differences are in any event trivial – no more than 
.01 for the two estimation periods, and seldom more than this for any subsequent period. 
Therefore, rather than pool the test data set with the estimation data set, the present work leaves 
the analogous series unchanged from those in Table 4. 
These analogues provide: (i) a benchmark for cumulative trial growth; and (ii) projection of 
year-end results. Consider benchmarking: if cumulative trial in a national launch is forecast to be 
50 percent at year-end, and only 20 percent has been achieved by week 16, is this high, low or 
just right?  Multiplying the year-end forecast (.50) by the analogy from Table 4 (.35 from week 
16) yields forecast cumulative trial of 17.5 percent. Therefore, a rate of 20 percent is on target, or 
even slightly high. Conversely, if cumulative trial has reached 15 percent by week 26, the 
analogue can be used to forecast the end of year trial rate. The analogue for week 26 is .62 of 
year-end trial. So the forecast for year-end trial is simply .15/.62 or 24 percent.   
As an illustration and further test of the method, the analogues in Table 4 can be applied to 
data from Singh, Scriven, Clemente, Lomax, and Wright (2012). They report in passing the 
average quarterly cumulative penetration for 47 brand extensions in UK packaged goods 
categories. In this case the quarters are 3 x 4 week periods, or 12 rather than 13 weeks. The 
appropriate analogues from Table 4 are therefore: the 12-week value for the first quarter (Q1); 
and, the 48-week value for the fourth quarter (Q4). Using these analogues, Q4 cumulative 
penetration is forecast to be .95/.25 or 3.82 times the Q1 value. The actual Q1 value in Singh et 
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al. (2012) is 1.4 percent so the forecast Q4 value is 5.35 percent (3.82 * 1.4 percent). This is 
within 6 percent of the observed Q4 value of 5.7 percent. This provides additional support for the 
use of the analogues in Table 4. 
Anecdotally, practitioners know they need to wait a few months for distribution to settle 
down before interpreting market performance data. Therefore, forecasting year-end cumulative 
trial from first quarter results, after distribution is established, is likely a very common problem. 
Table 4 indicates that 25 percent of year-end trial will be achieved after 12 weeks, and 31 percent 
after 13 weeks. To aid memorability, and in line with the principle of conservatism in forecasting 
(Armstrong, Green and Graefe, this issue), the second figure could reasonably be rounded up to 
one third. So managers wishing to know year-end cumulative trial could simply multiply the 
cumulative trial achieved at week 12 by four, or that achieved at week 13 by three. Given the 
rapid growth of consumer trial between 12 and 13 weeks, a 13-week time period should be used 
in preference to a 12-week time period, if possible. 
 
6. Discussion 
This work first investigates whether exponential trial growth models can be generalized beyond 
controlled test markets. That is, given the lesser control and greater variability of national 
markets, will these models still apply? This research yields a clear answer – the shape of 
cumulative trial curves in national markets is different, but the exponential trial growth models 
do still apply. 
Next, this research investigates whether analogous series can provide forecasts as accurate as 
the marketing science models. Again, the answer is clear - they do, in both BehaviorScan test 
markets and national product launches, and this enables a simple table of ratios to be used in 
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place of the marketing science models. Aside from the practical applications of this result, this 
confirms the worth of the analogous series approach (Armstrong, Green and Graefe, 201X, in 
this issue), for which empirical validation has been somewhat lacking (Armstrong 2001, p696, 
Principle 7.6). 
These results rest on a firm empirical base. To assess the method, each series 
is forecast separately while being held out from the estimation sample, and this procedure is 
repeated in two differentiated contexts. Validation of the method therefore involves 31 hold out 
tests including a differentiated replication. Furthermore, the original analogues are used to derive 
forecasts for a number of completely fresh data sets. For an additional 34 test data sets, the 
original analogues give more accurate forecasts than both a naive comparator and the best 
performing marketing science model. This is surprising as, unlike the analogues, the marketing 
science model was re-estimated for each of these 34 test data sets. Finally we apply the original 
analogues to a further 47 data sets previously reported in the literature and find that the forecast 
is within 6% of the observed value. 
These results fulfill Bass’ (1995) criteria for an empirical generalization, as a “pattern or 
regularity that repeats over different circumstances and can be described simply by 
mathematical, graphic or symbolic methods”. These results also meet Barwise’s (1995) criteria 
for a good empirical generalization, namely being based on repeated evidence and having scope, 
precision, parsimony, usefulness and a link with theory (i.e. stochastic models of consumer 
behavior). 
This generalization does stand in contrast to Meade and Islam’s (2001, p. 583) view that, 
“Even for diffusion processes that are homogenous in the sense that they describe the same 
innovation in different geographical areas, there is evidence that no single model performs well 
Commented [P1]: Copy editor please insert correct year 
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in all cases.”  However, aside from confirming Meade and Islam’s (2001, p. 587) simplicity 
principle, the results directly support their principle that, “unconditional forecasts based on a 
data-based estimate of a fixed saturation level form a difficult benchmark to beat.”   
The emergence of this empirical generalization also highlights one of the weaknesses of 
statistical modeling. Statistical modeling can be very good at identifying small effects and 
variations between markets; however, seeking best fits to individual series may miss large effects 
and patterns that are the same in many markets. The identification of these similar patterns is a 
strength of both the analogous series and empirical generalization approaches. Of course more 
sophisticated problems, such as early forecasting incorporating marketing covariates, or trial-
repeat modeling of long-term total demand, will require more sophisticated modeling. The 
present work makes no claim to solve such problems. Nonetheless, Khan’s (2002) results suggest 
that many practitioners do not undertake such sophisticated modeling, and for them the empirical 
generalization arising from the analogous series forecasting has practical application. Given 
Khan’s (2002) findings on management forecasting practice, complex approaches of the type Du 
and Kamakura (2011) and Liutec et al. (2012) report may not find widespread application. Also, 
their approaches are only validated for consumer packaged goods in one geographical location. 
In contrast, the simpler approach reported in the present work predicts trial for new launches, in 
different geographical locations, and for highly varied types of product.  
Ideally, those seeking to use this approach in new situations should develop their own 
analogues for these new situations, as follows: gather 6 to 12 previous time series of weekly 
cumulative trial data for new products; for each new product, divide each week by the 
cumulative trial achieved at the end of the first year; average the time series across products to 
yield a table of ratios similar to that in Table 4. As the national product launch data analyzed in 
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this study is quite varied, individual applications are unlikely to yield very different results. 
Nonetheless, special circumstances sometimes apply–as with the different analogues for the 
controlled test-markets – so checking the results in each new context would be wise. The 
analogues may be further decomposed to match different situations; for example, first movers 
versus followers, or successes versus failures. This decomposition remains a matter for further 
research, for which the techniques described in Green and Armstrong (2007) will provide a 
useful starting point. 
 
7. Summary 
This research extends findings from BehaviorScan test markets to national product launches 
monitored by consumer panels, and compares traditional marketing science forecasting methods 
with the simpler approach of analogous series. As expected, longer calibration periods are 
required for comparable accuracy in the messier environments of a national product launch. 
Nonetheless, the broad pattern of results for marketing science models is consistent between the 
two types of markets. Also, consistent with Armstrong (2001), Fader and Hardie (2001) and 
Meade and Islam (2001), simpler models perform well, the inclusion of consumer heterogeneity 
improves forecasts, and a never-triers parameter does not improve Forecast MAPE. These results 
should extend managerial and academic confidence in the use of marketing science models from 
BehaviorScan test markets to panel data for national product launches. Yet the simpler approach 
of analogous series forecasting performs just as well as the more complicated statistical models, 
and dominates the best performing marketing science model in the case of a challenging test 
involving 34 further new product launch data sets. 
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Analogous series do currently offer less scope for the inclusion of more complex behaviors; 
such as the effect of marketing covariates, or the revision of purchase probabilities after product 
experience. However, the use of structured analogies (Green and Armstrong 2007) may enable 
the analogous series approach to be extended to these more complex behaviors, and may also 
provide help to guidelines for disaggregating series into successful and unsuccessful new product 
launches. These remain matters for future research. 
Nonetheless, based on the present research, managers can use this approach for forecasting 
and benchmarking the simple cumulative trial metric widely used in new product launches. 
Managers may often simply wish to know, if they have achieved a certain level of trial after the 
first quarter, where will they be at the end of the year? Analogous series provide a simpler and 
better forecast than those available from marketing science models. 
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Table 1 
Summary of Data Sets for National Launches 
Behavior New Product n Country Innovativeness 
Household Purchases Biscuit Flavor 1719 New Zealand Brand Variant 
Household Purchases Health Snack 1569 New Zealand Category Entry 
Household Purchases Yellow Fat 2020 New Zealand Line extension 
GP Prescribing Drug Molecule 322 UK New to the UK 
GP Prescribing Drug Molecule 370 UK Category Entry 
GP Prescribing Drug Molecule 441 UK Category Entry 
GP Prescribing Drug Molecule 394 UK Category Entry 
Household Purchases Yellow Fat 3000 USA Line Extension 
Household Purchases Yellow Fat 3000 USA Line Extension 
Household Purchases Yellow Fat 3000 USA Category Entry 
Household Purchases Salad Dressing 4631 USA Line Extension 
Household Purchases Mayonnaise 4000 USA Line Extension 
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Table 2: Average Results for 13-week Calibration Period 
 National Launches 
 – 12 Panel Tracking 
Data sets 
Test Markets (HFW) 
 – 19 BehaviorScan Data 
sets 
Model  Forecast 
MAPE 
 
52w_APE 
 Forecast 
MAPE 
 
52w_APE 
Exp.-Gamma  27 28  17 23 
Exp.-Gamma w /NT  29 28  16 24 
Exp. w/NT  30 31  16 24 
Mean  28 29  16 24 
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Table 3 
Average Results for 26-week Calibration Period 
 National Launches 
 – 12 Panel Tracking 
Data sets 
Test Markets (HFW) 
 – 19 BehaviorScan Data 
sets 
Model  Forecast 
MAPE 
52w_APE  Forecast 
MAPE 
52w_APE 
Exp.-Gamma  9 9  10 12 
Exp.-Gamma w /NT  9 9  9 12 
Exp. w/NT  9 10  12 18 
Mean  9 10  10 14 
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Table 4 
Analogous Series of Cumulative Trial 
 
Proportion of Year-End 
Trial (Analogous Series) 
52w_APE 
 
Week 
National 
Launches 
Test 
Markets  
National 
Launches 
Test 
Markets  
4 0.05 0.32 84 33 
8 0.15 0.47 57 24 
12 0.25 0.58 26 22 
*13 0.31 0.60 13 23 
16 0.35 0.64 18 22 
20 0.45 0.70 11 18 
24 0.56 0.74 10 14 
*26 0.62 0.78 6 11 
28 0.64 0.80 7 9 
32 0.72 0.84 9 7 
36 0.78 0.88 7 6 
40 0.85 0.91 4 3 
44 0.89 0.94 4 2 
**48 0.95 0.98 5 1 
52 1.00 1.00 0 0 
*US national launches interpolated for these periods due to missing data 
**One New Zealand launch interpolated for this period due to missing data 
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Figure 1 
Analogous Series for Three Data Sets 
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Figure 2 
Normalized Trial for 34 Test Data Sets 
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 Table 5 
Comparative Results for Additional 34 Test Data Sets 
 13-week Calibration Period 26-week Calibration Period 
 Forecast 
MAPE 
52w 
_APE 
52w 
_MPE 
Forecast 
MAPE 
52w 
_APE 
52w 
_MPE 
12 National Launches - Exp.-Gamma 27 28  9 9  
19 BehaviorScan - Exp.-Gamma 17 23  10 12  
34 Test Data Sets – Straight Line 25 41 -33 13 25 -23 
34 Test Data Sets – Exp.-Gamma 20 28 7 12 15 1 
34 Test Data Sets - Analogous Series 12 26 -6 7 13 2 
 
